Initiated the Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa ...
At December 31, 2024, the Company's cash and cash equivalents grew to $912.8 million, compared to $713.7 million at December 31, 2023, which accounts for approximately $100.0 million of repurchased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback